Metformin: Established Metabolic Benefits and the Longevity Question

Metformin has a clear place in metabolic medicine. It helps lower blood glucose in people with type 2 diabetes, and research has shown that it can delay diabetes in some people at high risk. Those are meaningful benefits on their own.

Its long history of use has also made it a frequent subject of longevity interviews. The most useful way to understand metformin is to begin with its established role, then examine what researchers still need to learn about aging.

Haptic lists oral metformin among its current treatments. A clinician determines whether it fits a patient's medical needs. A listing under metabolic or longevity care should not be read as a promise that the medication reverses aging.

The strongest evidence starts with metabolic health

Metformin reduces glucose production by the liver and supports blood sugar management. FDA-approved metformin products are used with diet and exercise for type 2 diabetes. Using it specifically for diabetes prevention or longevity is outside that approved indication. The exact prescription and formulation matter. Prescribing information describes the approved use.

One of the landmark studies is the Diabetes Prevention Program. After about three years, metformin reduced the relative likelihood of developing type 2 diabetes by 31% compared with placebo in adults at high risk. Intensive lifestyle intervention reduced it by 58%. These are relative reductions in diabetes incidence, not percentages of body weight lost or years of life gained. NIDDK's study summary provides the context.

For an eligible patient, delaying diabetes is a practical health goal. The study also shows why medication and daily habits belong in the same conversation. Treatment decisions should account for the person's overall risk, preferences, and ability to sustain a plan.

Decide what success means for you

A prescription should come with a reason that can be explained in plain language. Is the goal to improve diabetes control? Address a particularly high risk of progression to diabetes? Something else?

Those goals should guide follow-up. An improvement in a glucose result can be valuable, but it should not be relabeled as proof of a slower aging rate. Similarly, a person can feel well and still need treatment for a measurable metabolic problem.

Bring previous glucose and A1c results to the visit when available. Also discuss the timing of meals, gastrointestinal symptoms, exercise, alcohol intake, and other medications. That information helps the clinician assess the whole situation rather than make a decision from one number.

What bloodwork contributes

For metabolic care, A1c and glucose help characterize the problem being treated and the response over time. Kidney function has a different purpose: it helps determine whether metformin is appropriate and how safely it can be used.

The FDA advises checking estimated glomerular filtration rate, or eGFR, before treatment and at least annually thereafter, with more frequent assessment for people at increased kidney risk. Metformin is contraindicated below an eGFR of 30, and starting treatment at an eGFR of 30 to 45 is not recommended. Certain contrast imaging procedures require a temporary interruption directed by the care team. FDA-approved prescribing information explains these precautions.

Vitamin B12 also deserves attention during longer-term use. Metformin can lower B12, and a clinician may investigate deficiency when there is anemia, numbness, or other relevant concern. MHRA's safety update explains when testing is useful. Supplements should address a documented need or clinical reason, not automatically become a growing list attached to every prescription.

Dosing follows the formulation and the patient

Immediate-release and extended-release tablets have different instructions. A clinician may increase the dose gradually to improve tolerability, guided by the treatment goal and kidney function. Extended-release tablets should be taken according to their own instructions, not substituted milligram for milligram into an improvised schedule.

There is no established “longevity dose” that has been proven to extend human life. A podcast protocol is not a substitute for the prescription on your medication label.

At follow-up, describe what you are actually taking and how it feels. That includes missed doses, stomach symptoms, and any new prescriptions. A plan that looks appropriate on paper may need adjustment to work in daily life.

Side effects and when the plan needs review

Diarrhea, nausea, and other gastrointestinal symptoms are common reasons people struggle with metformin. Rare but serious lactic acidosis is a major labeling concern, especially when risk factors such as severe kidney impairment are present. Acute illness, dehydration, surgery, heavy alcohol use, and imaging with contrast can change the safety discussion. Tell the treating team about metformin before a procedure. Metformin prescribing information contains the full warnings.

Do not assume that persistent symptoms are simply the price of treatment. Contact the prescriber so the cause, formulation, and dose can be reviewed.

Research outlook: what may come next

Aging researcher Nir Barzilai, MD, has discussed metformin and the rationale for testing interventions against age-related disease on The Peter Attia Drive. That is a useful introduction to a research question, not proof that metformin extends lifespan in healthy people.

An NIA workshop report describes the scientific rationale and remaining uncertainty around drugs targeting aging. Animal findings, changes in biomarkers, and observational associations do not settle whether healthy adults gain years of life from taking metformin.

Today, the strongest reason to consider metformin is an individualized metabolic indication. Future trials may clarify broader benefits, but no dependable date for an approved anti-aging indication can be promised.

Educational information, not an individual diagnosis or treatment plan. Follow the directions of your prescribing clinician.